Specialty Pharmaceutical Shareholder Recapitalisation
Multi-tiered credit structure combining a senior secured unitranche, subordinated mezzanine notes, and an asset-backed capex line to fund founding shareholder succession while financing sterile cleanroom expansion.
Preparation Date: November 2026. This transaction dossier is an analytical model illustrating capital stack design, secondary share buyout mechanics, regulatory capex financing, and upstream guarantee structures in regulated life sciences manufacturing. It does not represent an actual completed transaction, existing client engagement, or commitment of capital by Bayswater Transflow.
Shareholder Liquidity Without Diluting Founder Governance
An established specialty pharmaceutical platform generating 88,000,000 dollars in gross revenue and 13,600,000 dollars in adjusted operating EBITDA faces a dual transition: the retirement of a 50% founding co-shareholder requiring 30,000,000 dollars in buyout liquidity, and a mandatory 12,000,000 dollar capital expenditure requirement to upgrade cleanroom facilities for European and North American regulatory filings. A 45,000,000 dollar structured credit package resolves both requirements simultaneously while leaving the continuing founder in 100% operational control.
1. Commercial Situation and Succession Dynamics
The enterprise was founded twenty years ago by two equal co-promoters: an executive focused on technical operations, sterile engineering, and regulatory compliance, and a commercial partner managing sales, customer relationships, and corporate finance. Having built a highly profitable portfolio of oral solid dosage (OSD) generic formulations and specialized Active Pharmaceutical Ingredients (APIs), the commercial partner reached retirement age and requested full cash monetization of their 50% equity interest:
- The Control Dilemma: Traditional private equity buyout funds offered buyout capital only on the condition of acquiring majority control (51% to 100%), which would displace the technical founder, alter management incentives, and impose aggressive three-to-five year exit mandates.
- Secondary Share Purchase Mechanics: Because the $30,000,000 buyout consideration represents personal liquidity for the exiting shareholder rather than growth equity injected into the operating company balance sheet, traditional commercial banks refused to fund the transaction under conventional corporate debt covenants.
- Regulatory Capex Urgency: The company secured multi-year contract manufacturing agreements with European pharmaceutical distributors contingent upon upgrading its primary solid-dosage plant to EU-GMP Class 10,000 (ISO 7) cleanroom standards. Delaying this $12,000,000 capital expenditure would forfeit 28,000,000 dollars in contracted forward supply volume.
- Predictable Cash Flow Profile: The business generates recurring gross margins of 61.5% on solid formulations and 46.2% on API lines, backed by 36-month master supply agreements with top-tier generic marketing authorization holders across regulated markets.
2. Transaction Parties and Governance Architecture
| Role | Entity Description | Key Functional Responsibilities |
|---|---|---|
| Acquisition HoldCo | Special Purpose Vehicle (SPV) | Formed by continuing promoter; borrows Tranche A and Tranche B to purchase exiting shares; creates structured debt pushdown. |
| Operating Company | Pharmaceutical OpCo | Provides corporate upstream guarantee, pledges manufacturing fixed assets, and executes cleanroom capex. |
| Senior Unitranche Lender | Institutional Private Debt Fund | Provides $25,000,000 first-lien term loan and $8,000,000 capex/working capital line. |
| Mezzanine Provider | Subordinated Credit Specialist | Funds $12,000,000 junior subordinated notes with structured PIK coupon and non-voting phantom warrant coverage. |
| Continuing Founder | Promoter / Managing Director | Rolls 100% of existing equity interest, becomes sole shareholder, and commits to 5-year operating retention. |
3. Mathematically Reconciled Sources and Uses
The transaction reconciles capital sources against both secondary shareholder liquidity and primary operational expansion:
Sources of Funds
| Tranche A Senior Unitranche (First Lien) | $25,000,000 | 55.6% |
| Tranche B Subordinated Mezzanine Notes | $12,000,000 | 26.7% |
| Tranche C Capex Facility (Initial Draw) | $5,000,000 | 11.1% |
| Company Operating Cash Balance | $3,000,000 | 6.6% |
| Total Capital Sources | $45,000,000 | 100.0% |
Uses of Funds
| Retiring Shareholder Equity Buyout (50%) | $30,000,000 | 66.7% |
| Cleanroom Automation & HVAC Upgrades | $9,000,000 | 20.0% |
| EU-GMP & FDA Validation Audits | $3,000,000 | 6.7% |
| Debt Service Reserve Fund (DSRF - 6 Months) | $1,400,000 | 3.1% |
| Legal, Accounting, Tax & Advisory Fees | $1,600,000 | 3.5% |
| Total Capital Uses | $45,000,000 | 100.0% |
4. Regulatory Cleanroom Engineering and Capex Budget
The primary operational use of proceeds funds an advanced 12,000,000 dollar upgrade across the company's formulation and sterile filling facilities, audited by independent pharmaceutical engineering consultants:
| Engineering Scope Line Item | Allocated Budget | Technical Standard & Deliverable |
|---|---|---|
| Class 10,000 (ISO 7) Cleanroom Envelope | $3,800,000 | Modular non-shedding phenolic wall panels, coved corners, and epoxy flooring across 2,400 sq meters. |
| HVAC Air Handling Units & HEPA Filtration | $2,700,000 | Dedicated AHU cascading pressure zoning (15 Pa positive gradient) with terminal H14 HEPA filters. |
| Automated Sterile Vial & Ampoule Filling Line | $2,500,000 | Closed-barrier RABS filling system capable of 12,000 units per hour with automated weight verification. |
| Water for Injection (WFI) Generation System | $1,200,000 | Multi-column distillation plant producing 2,000 liters per hour with continuous conductivity monitoring. |
| Regulatory Validation & GMP Qualification Audits | $1,800,000 | DQ/IQ/OQ/PQ protocol execution and European Qualified Person (QP) declaration filings. |
5. Capital Stack Architecture and Pricing
| Tranche Component | Facility Size | Pricing & Yield | Maturity & Amortisation |
|---|---|---|---|
| Tranche A: Senior Unitranche | $25,000,000 | SOFR + 525 bps (1.0% SOFR floor) | 5 Years; 1.0% annual nominal amortisation; bullet at maturity. |
| Tranche B: Subordinated Mezzanine | $12,000,000 | 7.5% Cash Pay + 4.5% PIK (12.0% coupon) | 6 Years; non-amortising bullet; 2.5% phantom equity exit fee. |
| Tranche C: Capex / ABL Revolver | $8,000,000 ($5M drawn) | SOFR + 350 bps; 40 bps unused fee | 3 Years; revolving; pays down from operational cash flows. |
| Total Funded Structured Debt | $45,000,000 ($37M closing) | Blended Cost: 9.85% | Weighted Average Life: 5.2 Years |
6. Subordinated Mezzanine PIK Accretion Dynamics
The 12,000,000 dollar mezzanine facility utilizes a structured payment-in-kind (PIK) mechanism. While cash interest of 7.5% is serviced semi-annually from operating cash flows, the 4.5% PIK component compounds annually into principal, minimizing early cash drain during the cleanroom ramp:
| Facility Year | Opening Balance | 7.5% Cash Pay | 4.5% PIK Addition | Closing Balance |
|---|---|---|---|---|
| Year 1 | $12,000,000 | $900,000 | +$540,000 | $12,540,000 |
| Year 2 | $12,540,000 | $940,500 | +$564,300 | $13,104,300 |
| Year 3 | $13,104,300 | $982,823 | +$589,694 | $13,693,994 |
| Year 4 | $13,693,994 | $1,027,050 | +$616,230 | $14,310,224 |
| Year 5 | $14,310,224 | $1,073,267 | +$643,960 | $14,954,184 |
| Year 6 (Maturity) | $14,954,184 | $1,121,564 | +$672,938 | $15,627,122 |
7. Cash Flow Generation and Debt Service Waterfall
Servicing 37,000,000 dollars in initial funded debt requires disciplined cash flow modeling. The table below demonstrates operating cash conversion post-closing, assuming a 5.0% base SOFR:
| Cash Flow Waterfall Line Item | Year 1 (Closing) | Year 2 (Ramp) | Year 3 (Mature) |
|---|---|---|---|
| Adjusted Operating EBITDA | $13,600,000 | $15,200,000 | $17,500,000 |
| Less: Maintenance Capex | ($1,800,000) | ($1,900,000) | ($2,100,000) |
| Less: Cash Corporate Taxes (Effective 22%) | ($1,650,000) | ($2,050,000) | ($2,550,000) |
| Operating Cash Flow Available for Debt Service (CFADS) | $10,150,000 | $11,250,000 | $12,850,000 |
| Tranche A Senior Cash Interest (10.25%) | ($2,562,500) | ($2,536,875) | ($2,511,250) |
| Tranche B Mezzanine Cash Interest (7.5%) | ($900,000) | ($940,500) | ($982,823) |
| Tranche C Drawn Capex Interest (8.5%) | ($425,000) | ($425,000) | ($425,000) |
| Tranche A Mandatory Principal Amortisation | ($250,000) | ($250,000) | ($250,000) |
| Total Mandatory Cash Debt Service | ($4,137,500) | ($4,152,375) | ($4,169,073) |
| Free Cash Flow After Debt Service | +$6,012,500 | +$7,097,625 | +$8,680,927 |
| Debt Service Coverage Ratio (DSCR) | 2.45x | 2.71x | 3.08x |
8. Legal Architecture, Financial Assistance, and Debt Pushdown
Financing a shareholder buyout using corporate assets requires navigation of corporate benefit doctrines and statutory financial assistance limitations:
- Upstream Guarantee Solvency Testing: Because the Operating Company guarantees the debt incurred by HoldCo to acquire the retiring shareholder's stock, independent auditors perform statutory solvency testing. OpCo boards execute formal solvency declarations confirming that OpCo remains capable of paying debts as they fall due over the succeeding 12 months.
- Corporate Benefit Justification: Directors document tangible corporate benefits accruing to OpCo: eliminating deadlocked board control, preventing hostile third-party acquisitions, preserving executive technical talent, and securing committed financing for the EU-GMP cleanroom capex.
- Intercreditor Agreement (LMA Standard): Formal subordination deed executed between Tranche A and Tranche B lenders. Tranche B agrees to full payment standstill during any Tranche A default, yields priority over all asset security, and accepts that PIK interest is mandatory if OpCo fails to maintain a minimum 1.25x DSCR test.
- Regulatory Licences and DMF Pledges: Drug Master Files (DMFs), European Certificates of Suitability (CEPs), and manufacturing licences cannot be directly mortgaged without regulatory approvals. The security package establishes charges over commercial proceeds, patent assignments, formulation transfer agreements, and shares of the operational license-holding entity.
9. Technical and Regulatory Diligence Scope
Institutional private credit lenders underwriting pharmaceutical platforms demand rigorous technical verification prior to sanctioning term advances:
Pre-Sanction Technical Diligence Requirements
- cGMP Regulatory Audit History: Complete inspection audit reports from national regulatory bodies (US FDA Form 483s, warning letters, EU competent authority inspection certificates) across trailing five years.
- Batch Failure and Product Recall Records: Quality control review verifying out-of-specification (OOS) rates remain below industry standard thresholds (historical OOS rate of 0.38% against 1.50% ceiling).
- Cleanroom Engineering Specifications: Independent engineering review of HVAC air-handling designs, HEPA filtration schematics, differential pressure zoning, and cleanroom air change rates.
- API Supply Chain Integrity: Diligence into active substance regulatory filings, supplier qualification protocols, and raw material safety stock levels (90-day reserve buffer).
10. Cross-Border Tax Withholding, DTAA Substance, and Thin Capitalisation Limits
Deploying international private credit across cross-border holding vehicles requires rigorous compliance with domestic thin capitalisation ceilings, beneficial ownership tests, and statutory withholding tax regimes:
- EBITDA Interest Limitation Caps: In accordance with OECD BEPS Action 4 standards and domestic tax rules (such as Section 94B of the Indian Income-tax Act or the UK Corporate Interest Restriction), interest deductions paid to non-resident lenders or guaranteed by associated enterprises are capped at 30% of tax EBITDA. In this architecture, annual cash interest of $3,887,500 represents 28.58% of adjusted operating EBITDA ($13,600,000), remaining within the statutory deductibility ceiling.
- Treaty Withholding Tax Optimization: Where capital is routed via bilateral investment corridors (such as Luxembourg SCSp or Singapore HoldCo structures), beneficial ownership rules under applicable Double Taxation Avoidance Agreements (DTAAs) are satisfied by establishing genuine commercial substance, local resident directorships, and autonomous board decision-making. Standard cross-border interest withholding rates are mitigated from statutory 20% to 10% or 15% treaty rates.
- Transfer Pricing and Guarantee Fees: Because HoldCo issues corporate obligations backed by an OpCo upstream guarantee, an arm's length guarantee fee (calibrated at 50 to 75 basis points) is charged between entities. This transfer pricing structure is documented via formal benchmarking studies to withstand scrutiny from revenue authorities.
- Stamp Duty and Security Perfection Taxes: Pledges of industrial land titles, factory premises, and plant machinery incur ad valorem stamp duties in certain manufacturing jurisdictions. The security architecture utilizes centralized mortgage deeds registered with national company registrars (such as ROC and CERSAI) to cap statutory stamp duty expenses within the $1,600,000 advisory and closing budget.
11. Downside Scenarios, Risks, and Mitigants
| Identified Risk | Structural Severity | Mitigating Architecture |
|---|---|---|
| Regulatory Inspection Delay / 483 Notice | High | Existing revenue from domestic generic formulations generates 1.45x DSCR standalone without relying on new European cleanroom revenue. |
| Raw Material (API) Price Volatility | Medium | Long-term customer contracts include raw material indexation clauses passing price shocks exceeding 5% directly to commercial buyers. |
| Interest Rate Spike (SOFR +300 bps) | Medium | Mandatory interest rate cap purchasing SOFR protection at 6.0% for 50% of Tranche A notional; Tranche B mezzanine features fixed cash coupon. |
| Founder Key-Man Operational Dependency | High | 15,000,000 dollar Key Person life insurance policy assigned to collateral agent; elevation of Head of R&D and COO to board. |
12. Related Methodologies and Technical Analysis
For deeper examination of mezzanine subordination, unitranche structures, and regulatory due diligence, review our core guides:
Mezzanine Finance
Subordinated junior notes, PIK interest mechanics, and non-dilutive warrants.
Inspect Solution →Pharmaceuticals & APIs
Regulatory capex, WHO-GMP certifications, and supply chain working capital.
Inspect Sector →Capital Structure Design
HoldCo debt pushdowns, upstream guarantees, and intercreditor waterfalls.
Inspect Architecture →Important Disclosure
Information
Past performance and illustrative structures do not predict future returns or guarantee transaction completion. There can be no assurance that any potential mandate will achieve intended commercial terms or that counterparties will proceed to definitive execution. All commentary discusses broad commercial, industry, or sector situations and is provided for institutional information only.
Bayswater Transflow Ltd is an independent corporate advisory and transaction origination firm registered in England and Wales (Company No. 16277213). It is not authorised or regulated by the Financial Conduct Authority (FCA) and does not conduct regulated investment business, hold client money, arrange regulated activities, or advise the retail public on investments. Definitive documentation and regulated decisions remain exclusively with authorised counterparties and appointed professional counsel.
Next step
Structure a non-dilutive shareholder recapitalisation.
Consult with Bayswater on unitranche structuring, mezzanine subordination, and capex carve-outs.

